These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 2592812

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effects of lymphokine-activated killer cells and interleukin-2 on the ascites formation and the survival time of nude mice bearing human ovarian cancer cells.
    Oomori K, Kikuchi Y, Miyauchi M, Kita T, Iwano I, Kizawa I, Hirata J, Kuki E.
    J Cancer Res Clin Oncol; 1989; 115(3):217-20. PubMed ID: 2787797
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells.
    Schultz KR, Klarnet JP, Peace DJ, Cheever MA, Badger CC, Bernstein ID, Greenberg PD.
    Cancer Res; 1990 Sep 01; 50(17):5421-5. PubMed ID: 2386946
    [Abstract] [Full Text] [Related]

  • 5. [The rapid activation of human LAK cells and their inhibition on ovarian cancer at the advanced stage].
    Song YF, Zhao YN, Li J.
    Zhonghua Fu Chan Ke Za Zhi; 1994 Jun 01; 29(6):332-5, 381. PubMed ID: 8001405
    [Abstract] [Full Text] [Related]

  • 6. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].
    Wakizaka Y.
    Hokkaido Igaku Zasshi; 1992 Jul 01; 67(4):475-87. PubMed ID: 1330859
    [Abstract] [Full Text] [Related]

  • 7. [Effect of lymphokine activated killer from umbilical blood on human ovarian cancer in nude mouse models].
    He YD, Peng ZL, Liu SL, Wang H, Pan XL.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Sep 01; 38(5):810-2. PubMed ID: 17953364
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effects of cancer immunotherapy with indomethacin and interleukin-2 on murine hemopoietic stem cells.
    Saarloos MN, Khoo NK, Lala PK.
    Cancer Res; 1992 Dec 01; 52(23):6452-62. PubMed ID: 1423293
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
    Barton DP, Blanchard DK, Duan C, Roberts WS, Cavanagh D, DeCesare S, Djeu JY.
    J Soc Gynecol Investig; 1995 Dec 01; 2(6):762-71. PubMed ID: 9420887
    [Abstract] [Full Text] [Related]

  • 13. Adoptive immunotherapy of human pancreatic cancer with lymphokine-activated killer cells and interleukin-2 in a nude mouse model.
    Marincola FM, Da Pozzo LF, Drucker BJ, Holder WD.
    Surgery; 1990 Nov 01; 108(5):919-29. PubMed ID: 2237773
    [Abstract] [Full Text] [Related]

  • 14. IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile.
    Horton HM, Dorigo O, Hernandez P, Anderson D, Berek JS, Parker SE.
    J Immunol; 1999 Dec 15; 163(12):6378-85. PubMed ID: 10586027
    [Abstract] [Full Text] [Related]

  • 15. [Experimental study on the optimal treatment schedule for combination of BRM (immunostimulators, cultured killer cells or interleukin-2) and chemotherapy].
    Kan N, Okino T, Satoh K, Mise K, Teramura Y, Yamasaki S, Harada T, Ohgaki K, Tobe T.
    Gan To Kagaku Ryoho; 1990 Aug 15; 17(8 Pt 1):1421-7. PubMed ID: 2389941
    [Abstract] [Full Text] [Related]

  • 16. Local conditions in the host influence immunotherapy with interleukin-2 and LAK cells.
    Steller EP, Ottow RT, Eggermont AM, Marquet RL, Sugarbaker PH.
    Cancer Detect Prev; 1988 Aug 15; 12(1-6):81-90. PubMed ID: 3263202
    [Abstract] [Full Text] [Related]

  • 17. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
    Saijo N, Ozaki A, Ishihara J, Sakurai M, Sasaki Y, Takahashi H, Sano T, Hoshi A.
    Gan To Kagaku Ryoho; 1986 Apr 15; 13(4 Pt 2):1290-7. PubMed ID: 3488026
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.